Caricamento...
Dose selection and population pharmacokinetics of PEG-Intron in patients with chronic myelogenous leukaemia
AIMS: To assess the dose selection using population pharmacokinetics of Pegylated Intron-α2b (PEG-Intron) in patients with chronic myelogenous leukaemia (CML). METHODS: PEG-Intron 3–6 µg kg(−1) was administered subcutaneously once a week and blood samples were collected up to 48 weeks of treatment....
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Blackwell Science Inc
2007
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2000735/ https://ncbi.nlm.nih.gov/pubmed/16939523 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2006.02757.x |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|